Phase i study of safety and pharmacokinetics of ro7297089, an anti-bcma/cd16a bispecific antibody, in patients with relapsed, refractory multiple myeloma

HIGHLIGHTS

• who: Torben Plesner from the Vejle Hospital, University of Southern Denmark, Vejle, Denmark Peter MacCallum Cancer Center, Royal Melbourne Hospital, Melbourne and Sir Peter MacCallum Dept of Oncology University of Melbourne, Parkville, Australia have published the research: Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma, in the Journal: (JOURNAL) of June/16,/2020
• what: The aims were to evaluate the safety and tolerability of RO7297089 and to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs).
• how . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.